Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-1088 Phase 1 Multiple Ascending Dose and Drug-Drug Interaction Study
NCT06579300Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of MTK458 (14 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration of ABBV-1088 at 24 days, Time to Maximum Plasma Concentration of ABBV-1088 at 24 days and 7 more. Started Sep 2024; status: terminated.
02
Drugs
MTK458
Beyond the preview
Go deeper on NCT06579300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579300.